Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MICROSTEM: HLA-mismatched Microtransplantation in Myeloid Hemopathies
NCT03232268Phase 1Completed
- Sponsor
- Institut Paoli-Calmettes
- Start
- Mar 2018
- Primary completion
- Jan 2026
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of hematopoietic stem cells in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by Institut Paoli-Calmettes. Primary endpoint: Acute Graft versus Host Disease at 100 days. Started Mar 2018; status: completed.
02
Drugs
hematopoietic stem cells
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT03232268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03232268.